



BNP (h): 293T Lysate: sc-114214

BACKGROUND

Natriuretic peptides comprise a family of three structurally related molecules: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). ANP and BNP act mainly as cardiac hormones, produced primarily by the atrium and ventricle, respectively, while the gene encoding C-type natriuretic peptide is expressed mainly in the brain. These peptides possess potent natriuretic, diuretic and vasodilating activities and are implicated in body fluid homeostasis and blood pressure control. ANP, BNP and CNP are highly homologous within the 17 residue ring structure formed by an intramolecular disulfide linkage. The genes which encode for ANP and BNP map to human chromosome 1p36.22. The gene which encodes for CNP maps to human chromosome 2q24-qter.

REFERENCES

1. Saito, T., Matsuda, M., Yamaguchi, T., Akatsuka, S. and Nakagawa, S. 1975. Proceedings: Systemic-pulmonary arteriovenous fistula—a report of a case. *Jpn. Circ. J.* 39: 723.
2. Mair, J., Hammerer-Lercher, A. and Puschendorf, B. 2001. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. *Clin. Chem. Lab. Med.* 39: 571-588.
3. Cowie, M.R. and Mendez, G.F. 2002. BNP and congestive heart failure. *Prog. Cardiovasc. Dis.* 44: 293-321.
4. Hobbs, F.D., Davis, R.C., Roalfe, A.K., Hare, R., Davies, M.K. and Kenkre, J.E. 2002. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. *BMJ* 324: 1498.
5. Hall C. 2004. Essential biochemistry and physiology of NT-proBNP. *Eur. J. Heart Fail.* 6: 257-260.
6. Pfister, R., Scholz, M., Wielckens, K., Erdmann, E. and Schneider, C.A. 2004. Use of NT-proBNP in routine testing and comparison to BNP. *Eur. J. Heart Fail.* 6: 289-293.
7. Lellouche, N., De Diego, C., Cesario, D.A., Vaseghi, M., Horowitz, B.N., Mahajan, A., Wiener, I., Boyle, N.G., Fonarow, G.C. and Shivkumar, K. 2007. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. *Am. J. Cardiol.* 99: 242-246.
8. Sheen, V., Bhalla, V., Tulua-Tata, A., Bhalla, M.A., Weiss, D., Chiu, A., Abdeen, O., Mullaney, S. and Maisel, A. 2007. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. *Am. Heart J.* 153: 244.
9. Rauchenzauner, M., Haberlandt, E., Foerster, S., Ulmer, H., Laimer, M., Ebenbichler, C.F., Joannidis, M., Zimmerhackl, L.B., Stein, J. and Luef, G. 2007. Brain-type natriuretic peptide secretion following febrile and afebrile seizures—a new marker in childhood epilepsy? *Epilepsia* 48: 101-106.

CHROMOSOMAL LOCATION

Genetic locus: NPPB (human) mapping to 1p36.22.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

BNP (h): 293T Lysate represents a lysate of human BNP transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

BNP (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive BNP antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.